国际流行病学传染病学杂志
國際流行病學傳染病學雜誌
국제류행병학전염병학잡지
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY AND INFECTIOUS DISEASE
2009年
2期
103-105
,共3页
脂肪肝%复方牛胎肝提取物%易善复%联合治疗
脂肪肝%複方牛胎肝提取物%易善複%聯閤治療
지방간%복방우태간제취물%역선복%연합치료
Fatty liver%Compound embryonic bovine liver extract%Essentiale%Combined treatment
目的 观察安珐特联合易善复治疗非酒精性脂肪性肝炎的临床疗效.方法 选取62例非酒精性脂肪性肝炎患者,随机分为两组.观察组31例,采用安珐特联合易善复治疗;对照组31例,采用易善复治疗.疗程均为3个月.观察两组临床症状、肝功能指标、血脂改善效果.结果 治疗组疗效总有效率明显优于对照组(P<0.01).治疗组临床症状、ALT、AST、甘油三酯、总胆固醇改善明显,与对照组比较,各指标差异均有统计学意义(P<0.05).结论 安珐特联合易善复对改善脂肪肝及肝功能有明显效果.
目的 觀察安琺特聯閤易善複治療非酒精性脂肪性肝炎的臨床療效.方法 選取62例非酒精性脂肪性肝炎患者,隨機分為兩組.觀察組31例,採用安琺特聯閤易善複治療;對照組31例,採用易善複治療.療程均為3箇月.觀察兩組臨床癥狀、肝功能指標、血脂改善效果.結果 治療組療效總有效率明顯優于對照組(P<0.01).治療組臨床癥狀、ALT、AST、甘油三酯、總膽固醇改善明顯,與對照組比較,各指標差異均有統計學意義(P<0.05).結論 安琺特聯閤易善複對改善脂肪肝及肝功能有明顯效果.
목적 관찰안법특연합역선복치료비주정성지방성간염적림상료효.방법 선취62례비주정성지방성간염환자,수궤분위량조.관찰조31례,채용안법특연합역선복치료;대조조31례,채용역선복치료.료정균위3개월.관찰량조림상증상、간공능지표、혈지개선효과.결과 치료조료효총유효솔명현우우대조조(P<0.01).치료조림상증상、ALT、AST、감유삼지、총담고순개선명현,여대조조비교,각지표차이균유통계학의의(P<0.05).결론 안법특연합역선복대개선지방간급간공능유명현효과.
Objective To study the clinical effects of compound embryonic bovine liver extrac and polyene phos-phatidylcholine treatment for nonalcoholic fatty liver diseases. Methods 62 cases of nonalcoholic fatty liver diseases were selected and divided into two groups randomly: therapeutic group and control group. There were 31 cases in each group. In the 3-month treatment, the combination of compound embryonic bovine liver extrac and polyene phosphatidylcholine were used in the therapeutic group, and polyene phosphatidylcholine only in the control group. The clinical symptoms, ALT, AST, triglyeeride and total cholesterol of both groups were detected after the treatment. Results The total rate of effects in therapeutic group was better than that of control group (P<0.01), and also there were statistical differences in the recover of clinical symptoms, ALT, AST, triglyceride and total cholesterol between the two groups (P<0.05). Conclusions The combined treatment of compound embryonic bovine liver extmc and polyene phosphatidylcholine has an obviously therapeutic effeet for nonalcoholic fatty liver diseases.
